These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 33346915)
1. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Hajiran A; Chakiryan N; Aydin AM; Zemp L; Nguyen J; Laborde JM; Chahoud J; Spiess PE; Zaman S; Falasiri S; Fournier M; Teer JK; Dhillon J; McCarthy S; Moran-Segura C; Katende EN; Sexton WJ; Koomen JM; Mulé J; Kim Y; Manley B Clin Exp Immunol; 2021 Apr; 204(1):96-106. PubMed ID: 33346915 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma. Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D Front Immunol; 2021; 12():734646. PubMed ID: 34795663 [TBL] [Abstract][Full Text] [Related]
3. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy. Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492 [TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating CD39 Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075 [TBL] [Abstract][Full Text] [Related]
5. Intratumoral CXCL13 Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528 [TBL] [Abstract][Full Text] [Related]
6. Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. Fu Q; Xu L; Wang Y; Jiang Q; Liu Z; Zhang J; Zhou Q; Zeng H; Tong S; Wang T; Qi Y; Hu B; Fu H; Xie H; Zhou L; Chang Y; Zhu Y; Dai B; Zhang W; Xu J Eur Urol; 2019 May; 75(5):752-763. PubMed ID: 30293904 [TBL] [Abstract][Full Text] [Related]
8. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020 [TBL] [Abstract][Full Text] [Related]
9. Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy. Kraxner A; Braun F; Cheng WY; Yang TO; Pipaliya S; Canamero M; Andersson E; Harring SV; Dziadek S; Bröske AE; Ceppi M; Tanos T; Teichgräber V; Charo J Front Immunol; 2024; 15():1352632. PubMed ID: 39035007 [TBL] [Abstract][Full Text] [Related]
10. Immune Phenotype-Genotype Associations in Primary Clear Cell Renal Cell Carcinoma and Matched Metastatic Tissue. Sobottka B; Vetter V; Banaei-Esfahani A; Nowak M; Lorch A; Sirek A; Mertz KD; Brunelli M; Berthold D; de Leval L; Kahraman A; Koelzer VH; Moch H Mod Pathol; 2024 Oct; 37(10):100558. PubMed ID: 38969270 [TBL] [Abstract][Full Text] [Related]
12. Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte/macrophage infiltration into the clear cell renal cell carcinoma microenvironment. Xu W; Liu WR; Xu Y; Tian X; Anwaier A; Su JQ; Zhu WK; Shi GH; Wei GM; Huang YP; Qu YY; Zhang HL; Ye DW Int J Biol Sci; 2021; 17(9):2205-2222. PubMed ID: 34239350 [No Abstract] [Full Text] [Related]
13. Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). Catalano F; Brunelli M; Signori A; Rescigno P; Buti S; Galli L; Spada M; Masini C; Galuppini F; Vellone VG; Gaggero G; Maruzzo M; Merler S; Vignani F; Cavo A; Bimbatti D; Milella M; Dei Tos AP; Sbaraglia M; Murianni V; Damassi A; Cremante M; Maffezzoli M; Llaja Obispo MA; Banna GL; Fornarini G; Rebuzzi SE Future Oncol; 2024; 20(21):1495-1503. PubMed ID: 38682738 [TBL] [Abstract][Full Text] [Related]
14. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma. Kawashima A; Uemura M; Nonomura N Clin Genitourin Cancer; 2019 Dec; 17(6):e1147-e1152. PubMed ID: 31473121 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm. Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223 [TBL] [Abstract][Full Text] [Related]
16. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Şenbabaoğlu Y; Gejman RS; Winer AG; Liu M; Van Allen EM; de Velasco G; Miao D; Ostrovnaya I; Drill E; Luna A; Weinhold N; Lee W; Manley BJ; Khalil DN; Kaffenberger SD; Chen Y; Danilova L; Voss MH; Coleman JA; Russo P; Reuter VE; Chan TA; Cheng EH; Scheinberg DA; Li MO; Choueiri TK; Hsieh JJ; Sander C; Hakimi AA Genome Biol; 2016 Nov; 17(1):231. PubMed ID: 27855702 [TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of tertiary lymphoid structures and immune infiltration in ccRCC microenvironment revealed their clinical significances: a multicenter cohort study. Wang YQ; Chen WJ; Zhou W; Dong KQ; Zuo L; Xu D; Chen JX; Chen WJ; Li WY; Liu ZC; Jiang ZY; Tang YF; Qin YX; Wang LH; Pan XW; Cui XG J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908856 [TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma. Sammarco E; Rossetti M; Salfi A; Bonato A; Viacava P; Masi G; Galli L; Faviana P Med Oncol; 2024 May; 41(6):150. PubMed ID: 38740647 [TBL] [Abstract][Full Text] [Related]
19. The prognostic value and potential subtypes of immune activity scores in three major urological cancers. Shi B; Qi J J Cell Physiol; 2021 Apr; 236(4):2620-2630. PubMed ID: 32853461 [TBL] [Abstract][Full Text] [Related]
20. Upregulated GSDMB in Clear Cell Renal Cell Carcinoma Is Associated with Immune Infiltrates and Poor Prognosis. Cui Y; Zhou Z; Chai Y; Zhang Y J Immunol Res; 2021; 2021():7753553. PubMed ID: 34957313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]